AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$VERA

Fordyce Marshall sold $684K of VERA

Fordyce Marshall (PRESIDENT AND CEO) sold 18,500 shares of Vera Therapeutics, Inc. (VERA) at $37.00 ($0.68M total) on 2026-09-15 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Fordyce Marshall
Published Sep 17, 2026, 8:28 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 17, 2026, 8:36 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$VERA
Neutral
medium confidence
Mentioned
$VERA
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$VERANeutralLow
01

Why it matters

The transaction reduces insider ownership but is modest in size; investors may monitor for further insider activity.

02

Market read

Primary insider sale filing; modest relevance for short-term traders.

03

What to watch

Potential upcoming clinical data or financing events not disclosed.

Relevance 4/10Novelty 4/10Timing: filed Sep 17 2026

Background

Form 4 filing by Vera Therapeutics' CEO discloses a sale of shares under a pre-arranged plan.

Company-level read

Ticker impact

$VERANeutralMedium confidence
Context

CEO Fordyce Marshall sold 18,500 shares for $684,500 via a 10b5-1 plan, reducing his stake to 235,244 shares.

Expected impact

Potential slight downward pressure in the near term.

Evidence & confidence

Form 4 filing is primary source; sale size under $1M caps relevance, but insider is CEO, so market watches.

Market effects

Sector

Minimal impact on biotech sector; typical insider sell.

Regional

None

Global

None

Counterpoint

What could challenge this read

Insider sell could be routine 10b5-1 execution, not a negative signal.

Key entities

  • Company
    Vera Therapeutics, Inc.

    Biotech firm listed on Nasdaq (VERA).

  • Person
    Fordyce Marshall

    President and CEO of Vera Therapeutics.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

VERA insider trading history →

Related articles

$VERAMed

Vera Therapeutics Inc (VERA) (Q3 2026) Earnings Call Highlights: TRUTAKNA Launch Off

Vera Therapeutics (VERA) reported $10.3M in Q3 TRUTAKNA revenue, split evenly between inventory and demand. The company expects demand to rise. Chief Medical Officer Robert Brenner discussed potential label changes post-ORIGIN 3 data, and Chief Commercial Officer Matt Skelton provided updates on prescription trends and market access. Vera aims for 50% covered lives by year-end. The company is also conducting a dose-range study for atacicept, with data expected later this quarter.

finance.yahoo.com
$VERAMedAI 8/10

Vera Therapeutics Q3 Earnings Call Highlights

Vera Therapeutics (VERA) reported Q3 net loss of $93.7M, up from $80.3M YoY, due to launch spending. TRUTAKNA showed positive kidney disease progression results, with 76% risk reduction vs. placebo. Vera has $459M in cash and expects U.S. approval in mid-2027. Additional studies on atacicept are ongoing.

finance.yahoo.com
$VERAMedAI 8/10

Vera Therapeutics (VERA) Q3 2026 Earnings Call Transcript

Vera Therapeutics (VERA) reported strong early demand for TRUTAKNA, its newly FDA-approved therapy for IgA nephropathy, with 700 patient start forms since July. The company submitted a supplemental biologics licensing application for full FDA approval, citing final efficacy results from the ORIGIN 3 trial, which showed a 76% reduction in kidney disease progression risk. Vera also plans to submit a marketing authorization application in Europe in Q1 2027.

finance.yahoo.com
$VERAMed

Vera Therapeutics Provides Business Update and Reports Third Quarter 2026 Financial Results

Vera Therapeutics, Inc. (VERA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Vera Therapeutics Provides Business Update and Reports Third Quarter 2026 Financial Results • TRUTAKNA® (atacicept-vymj) U.S. launch building early momentum following July 7 accelerated approval by the U.S. Food and Drug Administration (FDA) with approximately 700 Pa

SEC EDGAR 8-K